ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 400 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Meredith Cook also recently made the following trade(s):
- On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total transaction of $23,816.00.
- On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00.
ANI Pharmaceuticals Price Performance
Shares of ANIP opened at $62.49 on Friday. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The stock has a market cap of $1.36 billion, a PE ratio of -113.62 and a beta of 0.62. The firm has a 50-day simple moving average of $58.40 and a two-hundred day simple moving average of $58.09. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.
Institutional Investors Weigh In On ANI Pharmaceuticals
Analyst Ratings Changes
ANIP has been the topic of several research reports. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They issued an “overweight” rating and a $85.00 price target on the stock. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Finally, StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.75.
View Our Latest Stock Report on ANIP
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
- Five stocks we like better than ANI Pharmaceuticals
- Most active stocks: Dollar volume vs share volume
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Learn Technical Analysis Skills to Master the Stock Market
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Some of the Best Large-Cap Stocks to Buy?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.